GlassScriptPhysician profile
Barry J Gross
NPI 1811952294
$8,102.33
in general payments reported to CMS, 2019-2025
37 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,569 · 2020: $449 · 2021: $703 · 2022: $1,237 · 2023: $1,491 · 2024: $1,140 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,099 · Education: $44.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,098.84 |
| Education | $44.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,406.17 | 2021-2025 | |
| Indivior INC. | $721.52 | 2019-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $636.02 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $565.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Alkermes, INC. | $521.35 | 2020-2025 | Vivitrol, Vivitrol |
| Axsome Therapeutics, INC. | $512.34 | 2023-2025 | Sunosi, Auvelity |
| Eisai INC. | $413.62 | 2020-2022 | |
| Novo Nordisk INC | $355.86 | 2019-2025 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $347.33 | 2022-2025 | Quviviq, Quviviq |
| Glaxosmithkline, LLC. | $307.76 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Ironshore Pharmaceuticals INC. | $280.40 | 2019-2022 | |
| Braeburn INC. | $260.57 | 2023-2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $208.40 | 2021-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $168.91 | 2021-2023 | Verquvo |
| Paratek Pharmaceuticals, INC. | $156.14 | 2022-2024 | Nuzyra |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.